Obeticholic - Latest Advances

Recent Advances in Primary Biliary Cholangitis Treatment.

Journal: Clinics in liver disease

Published: October 18, 2025

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Journal: Expert opinion on investigational drugs

Published: October 13, 2025

New therapeutic approaches for the treatment of primary biliary cholangitis

Journal: Medecine sciences : M/S

Published: September 08, 2025

FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity.

Journal: Science translational medicine

Published: August 13, 2025

Present and Future Perspectives in the Treatment of Liver Fibrosis.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 05, 2025

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Journal: Expert review of gastroenterology & hepatology

Published: July 30, 2025

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 15, 2025

Clostridial-dominated gut microbiota promotes 7α-dehydroxylation of obeticholic acid to lithocholic acid in cholestasis treatment.

Journal: Biochemical and biophysical research communications

Published: July 13, 2025

Investigating Intestinal Farnesoid X Receptor functions at the Intestinal Mucosal Barrier and in the Intestinal Microbiota in a Biliary Obstruction Mouse Model.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Published: July 07, 2025

Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Published: July 07, 2025

Innate immunity of bile and cholangiocytes in primary biliary cholangitis.

Journal: Frontiers in immunology

Published: June 27, 2025

Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Published: June 26, 2025

Filters

Recent Advances in Primary Biliary Cholangitis Treatment.

Recent Advances in Primary Biliary Cholangitis Treatment.

An update on novel investigational agents for the treatment of primary biliary cholangitis.

An update on novel investigational agents for the treatment of primary biliary cholangitis.

New therapeutic approaches for the treatment of primary biliary cholangitis

New therapeutic approaches for the treatment of primary biliary cholangitis

FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity.

FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity.

Present and Future Perspectives in the Treatment of Liver Fibrosis.

Present and Future Perspectives in the Treatment of Liver Fibrosis.

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders.

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders.

Clostridial-dominated gut microbiota promotes 7α-dehydroxylation of obeticholic acid to lithocholic acid in cholestasis treatment.

Clostridial-dominated gut microbiota promotes 7α-dehydroxylation of obeticholic acid to lithocholic acid in cholestasis treatment.

Investigating Intestinal Farnesoid X Receptor functions at the Intestinal Mucosal Barrier and in the Intestinal Microbiota in a Biliary Obstruction Mouse Model.

Investigating Intestinal Farnesoid X Receptor functions at the Intestinal Mucosal Barrier and in the Intestinal Microbiota in a Biliary Obstruction Mouse Model.

Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model.

Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model.

Innate immunity of bile and cholangiocytes in primary biliary cholangitis.

Innate immunity of bile and cholangiocytes in primary biliary cholangitis.

Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function.

Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function.